UBS Group’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

UBS Group’s Portfolio GNRX Stock Details GNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-660	Closed	-$15K	–	8510
2019 Q1	$15K	Buy	+660	New	+$14.5K	﹤0.01%	6573
2017 Q4	–	Sell	-50	Closed	-$1K	–	8461
2017 Q3	$1K	Sell	50 -3,395	-99%	-$75.2K	﹤0.01%	7663
2017 Q2	$78K	Buy	3,445 +445	+15%	+$10K	﹤0.01%	5336
2017 Q1	$68K	Hold	3,000	–	–	﹤0.01%	5311
2016 Q4	$64K	Sell	3,000 -32,000	-91%	-$716K	﹤0.01%	5640
2016 Q3	$848K	Sell	35,000 -1,050	-3%	-$26.3K	﹤0.01%	3542
2016 Q2	$860K	Sell	36,050 -18,950	-34%	-$452K	﹤0.01%	3508
2016 Q1	$1.32M	Buy	+55,000	New	+$1.32M	﹤0.01%	3031

UBS Group's GNRX Position: Q2 2019 in Review

UBS Group sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q2 2019, closing a stake of 660 shares — an estimated $15K sold.

UBS Group first reported a position in GNRX in Q1 2016 and held it in 8 quarters. The position peaked at $1.32M in Q1 2016. 0 funds tracked by Wall St. Rank hold GNRX as of Q2 2019.

UBS Group reported no remaining VanEck Vectors Generic Drugs ETF position as of Q2 2019 after selling out during the quarter.
UBS Group sold 660 VanEck Vectors Generic Drugs ETF shares in Q2 2019, an estimated $15K.
UBS Group first reported a position in VanEck Vectors Generic Drugs ETF in Q1 2016 and held it in 8 quarters.
UBS Group's VanEck Vectors Generic Drugs ETF position peaked at $1.32M in Q1 2016.
0 funds tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q2 2019.

Based on UBS Group's 13F filing for Q2 2019, filed 14 Aug 2019.